Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Childhood Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Conditions
Brief summary
This pilot research trial studies biomarkers in bone marrow samples from pediatric patients with high risk acute myeloid leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Detailed description
PRIMARY OBJECTIVES: I. To provide a detailed, molecular map of pediatric high risk acute myeloid leukemia (AML). II. To identify mutations, expression profile, gene copy number, loss of heterozygosity (LOH) status and genomic methylation patterns in order to identify novel changes associated with pediatric AML. III. To generate fibroblast cell lines in order to obtain germline nucleic acids from marrow specimens from AML patients with induction failure. IV. To identify genomic alterations contributing to induction failure in childhood AML. OUTLINE: Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome single nucleotide polymorphism (SNP) genotyping, expression, and methylation profiling.
Interventions
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of acute myeloid leukemia * High-risk disease * Treated on COG-AAML03P1 or COG-AAML0531 * Meets the following criteria: * Initial remission with no known adverse risk factors * High quantity and quality of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) available * Highly enriched specimens with \>= 50% blast available
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detailed molecular map of pediatric high-risk acute myeloid leukemia | Baseline |
| Mutations in identifying novel changes associated with pediatric AML | Baseline |
| Expression profile in identifying novel changes associated with pediatric AML | Baseline |
| Gene copy number in identifying novel changes associated with pediatric AML | Baseline |
| LOH status in identifying novel changes associated with pediatric AML | Baseline |
| Genomic methylation patterns in identifying novel changes associated with pediatric AML | Baseline |
| Genomic and transcriptome alterations associated with induction failure | Baseline |
| Genomic alterations contributing to induction failure in childhood AML | Baseline |
Countries
United States
Outcome results
None listed